Avalo Therapeutics (NASDAQ: AVTX) Chief Medical Officer Mittie Doyle sold 1,000 shares of the company’s common stock on August 17, 2026, at $20.00 per share, totaling $20,000 in proceeds. The transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 13, 2025.
Concurrently, Doyle exercised stock options to acquire an additional 1,000 shares at $12.65 per share, amounting to $12,650. The options vest in stages, with 25% already vested as of July 15, 2025, and the remainder scheduled to vest in equal monthly installments over the next three years, contingent on continued employment.
Following the sale, Doyle retains direct ownership of 51,776 shares of Avalo Therapeutics common stock and holds 123,750 derivative securities in the form of stock options. The company’s shares were trading at $19.74 on the day of the transaction, reflecting a 108% return over the past 12 months.
Analysts have issued bullish price targets for Avalo Therapeutics, ranging from $30 to $60. However, InvestingPro analysis characterizes the stock as overvalued relative to its fair value estimate. Recent additions to major indexes include the Russell 2000 and Russell 3000, alongside positive analyst actions such as Cantor Fitzgerald’s reiteration of an Overweight rating and Leerink’s initiation with an Outperform rating and a $38.00 price target.
In corporate news, Ron Philip joined Avalo Therapeutics’ board of directors, bringing over three decades of biopharmaceutical experience. Philip will serve on the Compensation Committee and the Science, Development and Commercial Advisory Committee, effective through the 2027 Annual Meeting of Stockholders.
